Compare · SES vs TMO
SES vs TMO
Side-by-side comparison of SES AI Corporation (SES) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- SES operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $175.70B, about 403.2x SES ($435.8M).
- Over the past year, SES is up 13.5% and TMO is up 15.7% - TMO leads by 2.2 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 8 for SES).
- TMO has more recent analyst coverage (25 ratings vs 7 for SES).
- Company
- SES AI Corporation
- Thermo Fisher Scientific Inc
- Price
- $1.18-11.99%
- $472.71-1.94%
- Market cap
- $435.8M
- $175.70B
- 1M return
- +19.90%
- -0.15%
- 1Y return
- +13.53%
- +15.69%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 8
- 17
- Recent ratings
- 7
- 25
SES AI Corporation
SES AI Corporation engages in the development and production of high-performance Lithium-metal rechargeable batteries for electric vehicles and other applications. The company was founded in 2012 and is headquartered in Boston, Massachusetts.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest SES
- CHIEF LEGAL OFFICER Pilkington Kyle sold $30,007 worth of shares (25,000 units at $1.20) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,023,548 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Liu Yi Ray was granted 331,858 shares (SEC Form 4)
- CHIEF LEGAL OFFICER Pilkington Kyle was granted 353,982 shares, increasing direct ownership by 51% to 1,048,548 units (SEC Form 4)
- Director Luo Eric was granted 141,593 shares, increasing direct ownership by 37% to 524,993 units (SEC Form 4)
- CEO & CHAIRMAN Hu Qichao was granted 1,504,425 shares, increasing direct ownership by 38% to 5,449,607 units (SEC Form 4)
- Director Boyd Andrew J was granted 141,593 shares, increasing direct ownership by 48% to 437,889 units (SEC Form 4)
- Director Ma Jiong was granted 141,593 shares, increasing direct ownership by 37% to 524,993 units (SEC Form 4)
- CHIEF TECHNOLOGY OFFICER Xu Kang was granted 221,239 shares, increasing direct ownership by 38% to 801,635 units (SEC Form 4)
- NeoVolta Appoints Jing Nealis as Chief Financial Officer
- SEC Form 3 filed by new insider Liu Yi Ray
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)